



# ZILBRYSQ (zilucoplan) Is Available Exclusively Through a Single Specialty Pharmacy— PANTHERx Rare

UCB is committed to helping adult patients access ZILBRYSQ, which is administered at home once daily via subcutaneous self-injection. Prescriptions will be fulfilled exclusively through PANTHERx Rare. ZILBRYSQ is available only through a restricted program called [ZILBRYSQ REMS](#).

Prescriptions can be submitted to PANTHERx Rare through the following options:

| ePrescribe       | Fax          | Phone        |
|------------------|--------------|--------------|
| NPI #1659762524* | 412-567-6135 | 833-418-7760 |

\*Use this NPI number when submitting a prescription electronically to PANTHERx Rare.

**For more information, visit [pantherxrare.com](http://pantherxrare.com) or call 833-418-7760**

## INDICATION

ZILBRYSQ (zilucoplan) is indicated for the treatment of gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

## IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

### WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors; ZILBRYSQ is a complement inhibitor. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

- Complete or update meningococcal vaccination at least 2 weeks prior to administering the first dose of ZILBRYSQ, unless the risk of delaying therapy outweighs the risk of developing a meningococcal infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccinations in patients receiving a complement inhibitor.
- Persons receiving ZILBRYSQ are at increased risk for invasive disease caused by *N. meningitidis*, even if they develop antibodies following vaccination. Monitor patients for signs of meningococcal infections and evaluate immediately if infection is suspected.

ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS.

gMG=generalized myasthenia gravis; NPI=National Provider Identifier; REMS=Risk Evaluation and Mitigation Strategy.

**Please refer to the next page for additional Important Safety Information.**

**Please refer to the full Prescribing Information, including Boxed Warning for serious meningococcal infections, provided by the UCB representative and visit [ZILBRYSQhcp.com](http://ZILBRYSQhcp.com).**

**IMPORTANT SAFETY INFORMATION (cont'd)**

**CONTRAINDICATIONS**

ZILBRYSQ is contraindicated in patients with unresolved *Neisseria meningitidis* infection.

**WARNINGS AND PRECAUTIONS**

**Other Infections**

Use caution when administering ZILBRYSQ to patients with any other systemic infection.

**Pancreatitis And Other Pancreatic Conditions**

Pancreatitis and pancreatic cysts have been reported in patients treated with ZILBRYSQ. Discontinue ZILBRYSQ in patients with suspected pancreatitis and initiate appropriate management until pancreatitis is ruled out or has resolved.

**ADVERSE REACTIONS**

The most common adverse reactions ( $\geq 10\%$ ) were injection site reactions, upper respiratory tract infections, and diarrhea.

**Please refer to the full Prescribing Information, including Boxed Warning for serious meningococcal infections, provided by the UCB representative and visit [ZILBRYSQhcp.com](https://www.zilbrysqhcp.com). For more information about ZILBRYSQ, visit [ZILBRYSQhcp.com](https://www.zilbrysqhcp.com).**

**For additional information, contact UCBCares<sup>®</sup> at 1-844-599-CARE (2273).**

**Reference:** ZILBRYSQ [prescribing information]: Smyrna, GA: UCB, Inc.



ZILBRYSQ<sup>®</sup> and UCBCares<sup>®</sup> are registered trademarks of the UCB Group of Companies.  
All other trademarks are the property of their respective holders.  
©2023 UCB, Inc., Smyrna, GA 30080. All rights reserved.  
US-P-ZL-MG-2300094 | December 2023